Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04364217
Other study ID # 2019P003424
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 25, 2020
Est. completion date July 2025

Study information

Verified date February 2023
Source Massachusetts General Hospital
Contact Nisrine Kawa, MD
Phone 6177242168
Email nikawa@mgh.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hypertrophic Burn Scars (HTBS) are often treated with Fractional CO2 laser therapy to improve cosmetic appearance. It has been noted that this leads to a reduction in the pain and itch associated with this type of scars. While this phenomenon is commonly described in the literature, the mechanism of pain and itch reduction in unclear. The investigators aim to better understand this process by histological evaluation of HTBS at different stages of laser treatment.


Description:

During our study, patients with painful and/or itchy burn scars will undergo standard treatment with fractional CO2 laser. In addition to the standard of care treatment, participants will undergo skin biopsies and be asked to complete Patient Reported Outcome Measure questionnaires related to their HTBS. Burn scars will also undergo standard and 3 dimensional photography at the different stages of treatment. Biopsy samples will undergo various staining techniques to establish the changes in tissue that occur with the laser treatment. This information will also be correlated with the symptomatic changes.


Recruitment information / eligibility

Status Recruiting
Enrollment 28
Est. completion date July 2025
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patient must have a hypertrophic burn scar treated by skin grafts or allowed to heal secondarily - Burn must have occurred within the last 2 years from time of recruitment - Patient must have symptoms of pain and/or itch and/or hypersensitivity in the hypertrophic burn scar area - Patient must already be planning to undergo laser treatment for their burn scar - Patient must be willing to undergo biopsy procedures - Patient must be willing and able to participate in the study with a year of follow-up - Not be pregnant or planning to become pregnant during the treatment phase of the study Exclusion Criteria: - Medical Conditions that preclude laser treatment - Active tanning, including the use of tanning booths, during the course of the study - Inability to complete surveys - Previous laser (PDL, CO2), surgical reconstructive treatment procedures done on the hypertrophic burn scar - Current treatment with other procedures or drugs (experimental or other) in area of interest - Medications that interfere with wound healing (oral steroids, immunosuppressive medications, chemotherapy or other) - Medication for itch (steroids, antihistamines, or other) - Medication for pain (opioids, topical pain treatment, gabapentin, ondasetron, paroxetine or other) - Adverse reactions to topical or local anesthetic agents needed for this study, if no alternative to the said agent exists - The study area should not be part of a contracture or other hypertrophic scar that would be better treated with surgical procedures. - The study scar must not be adjacent to/in continuity with areas of HTBS that are planning to be treated with surgical interventions. - Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject - Patient suffers from epilepsy or seizure disorder.

Study Design


Intervention

Device:
Luminis ultrapulse fractional ablative carbon dioxide laser
This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Histological change in nerve density The investigators will stain the collected skin with markers specific to nerves to in order to count the number of nerves per biopsy area. 7 months
Primary Histological change in nerve morphology The investigators will stain the collected skin with markers specific to nerves to in order to compare the size and shape of cutaneous nerves before and after treatment. This will be based on subjective evaluation and not a predetermined scale. 7 months
Secondary Symptomatic Improvement Assessment Patient Reported Outcome Measures will be collected via the Patient and Observer Scar Assessment Scale (POSAS). This is a validated questionnaire that includes 5 physician-completed parameters and 6 patient-reported measures. Each parameter is rated from 1-10 with a score of 1 representing "skin that appears close to normal" and 10 representing the "worst scare imaginable". Overall, the final score will range from 11( best outcome) to 110 (worst outcome).
Physician parameters relate to the scar appearance such as color and thickness of the scar; while the patient-reported parameters also include symptomatic factors, such as degree of pain associated with the scar
7 months
See also
  Status Clinical Trial Phase
Completed NCT03376620 - Role of Topical Putrescine (Fibrostat) for Prevention of Hypertrophic Scars in Mammoplasty Patients Phase 3
Terminated NCT03935594 - Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars Phase 2
Recruiting NCT03561376 - Zinc Oxide Versus Petrolatum Following Skin Surgery Early Phase 1
Recruiting NCT06033430 - Effectiveness of Dry Needling in Linear Scar Tissue N/A
Recruiting NCT03631368 - Treatment of Hypertrophic Scars With Intradermal Botox Phase 2
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Recruiting NCT02168634 - The Use of Botulinum Toxin in the Treatment of Itching From Hypertrophic Scar -- A Randomised Controlled Trial N/A
Completed NCT02030275 - A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults Phase 2
Recruiting NCT04506255 - Silicone Taping for the Improvement of Abdominal Donor Site Scars N/A
Not yet recruiting NCT04593706 - Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) N/A
Completed NCT04643223 - Effect of Elastic Bandage With Tension on the Inflammatory Response of Hypertrophic Scars N/A
Completed NCT03986346 - The Vascularity Changes of Scars With Laser Therapy N/A
Completed NCT04619589 - Characterization of Dyschromic Hypertrophic Scar
Completed NCT06347081 - Effect of Nd-YAG Laser on Hypertrophic Scar N/A
Completed NCT05412745 - Class I Medical Device on Post-surgical Scars N/A
Terminated NCT03403621 - Hypertrophic Scar Prevention by Novel Topical Gel Application Phase 1/Phase 2
Completed NCT00754247 - A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars Phase 4
Recruiting NCT03692273 - Randomized Control Trial of CO2 Laser to Treat Hypertrophic Burn Scar N/A
Completed NCT03795116 - Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention Phase 2
Not yet recruiting NCT03850119 - Nanofat on Wound Healing and Scar Formation N/A